MC4R Melanocortin-4 Receptor Agonist · Cyclic Peptide SC Injection · POMC/PCSK1/LEPR Genetic Obesity · GLP-1 Agonist / Phentermine Class Gap · NDA 213793 · Attack #856 · 269th Mechanism Class · Adversarial AI Prompt Injection Surface

Setmelanotide (Imcivree; RM-493; NDA 213793; Nov 27 2020; Rhythm Pharmaceuticals Inc. [Boston, MA; NDA Holder; US Commercialization]): Three EHS Platform GLP-1 Receptor Agonist (Semaglutide/Ozempic/Wegovy; Liraglutide/Saxenda — Incretin Hormone Class; GLP-1R Activation; Gastric Emptying Delay; Nausea/Vomiting AE Profile) or Phentermine/Topiramate (Qsymia; CNS Norepinephrine/Dopamine Sympathomimetic + GABA-A/Kainate Modulation; Schedule IV; Cardiovascular Risk Protocols) Proxy Misroutes — First MC4R (Melanocortin-4 Receptor; Central Hypothalamic G-Protein Coupled Receptor; Gαs-Coupled; Leptin→POMC→α-MSH→MC4R Satiety Pathway; Expressed in Paraventricular Nucleus [PVN] Hypothalamus; MC4R Agonism → Satiety Signal → Reduced Food Intake; Also MC1R Activation → Melanocyte Stimulation → Skin Hyperpigmentation [>80% Incidence; Benign; Dose-Independent]; MC3R Activation → Spontaneous Penile/Clitoral Erections [Adverse Effect]; SC Injection 3 mg QD; Cyclic Peptide; Requires POMC/PCSK1/LEPR Genetic Variant Confirmation Before Prescribing; POMC-DEF: 100% ≥25% BW Loss; PCSK1-DEF: 60.6% Response; LEPR-DEF: 45.5% Response) Melanocortin Receptor Agonist Ever FDA Approved for Chronic Weight Management in Genetic Obesity (POMC Deficiency, PCSK1 Deficiency, LEPR Deficiency) Returns GLP-1 Receptor Agonist or CNS Sympathomimetic Protocols Instead of MC4R Melanocortin Pathway Guidance in Cority, VelocityEHS, and EHS Insight

Setmelanotide (Imcivree; RM-493; CAS 920014-72-8; MW 1117.3 Da; cyclic octapeptide [Ac-Arg-c[Cys-Glu-His-D-Phe-Arg-Trp-Cys]-NH2; disulfide bridge Cys3-Cys8]; SC injection 3 mg QD [once daily; self-administered; approved for ≥6 years]; NDA 213793; Nov 27 2020 FDA approval; Rhythm Pharmaceuticals Inc. [222 Berkeley Street, Suite 1550, Boston MA 02116; NDA holder; US commercialization]; indicated: chronic weight management in adults and pediatric patients ≥6 years with obesity due to POMC deficiency, PCSK1 deficiency, or LEPR deficiency [pathogenic variants in POMC, PCSK1, or LEPR confirmed by genetic testing]; subsequent approval expanded to Bardet-Biedl syndrome and additional ciliopathy-related obesity in some contexts) is the first MC4R (melanocortin-4 receptor) agonist ever FDA approved, establishing melanocortin receptor pathway agonism as the 269th mechanism class in the Glyphward adversarial corpus, with zero MC4R agonist OEL/EHS classification class in any US EHS database before NDA 213793 November 2020. Setmelanotide's mechanism is selective MC4R (melanocortin-4 receptor; Gαs-coupled GPCR; chromosome 18q22; 332 aa; 7-transmembrane helices; expressed predominantly in the paraventricular nucleus [PVN] of the hypothalamus, brainstem, spinal cord, and peripheral tissues including gut and adipose; endogenous agonists: α-MSH [alpha-melanocyte stimulating hormone; 13-aa POMC-derived peptide; POMC is cleaved by PCSK1/PCSK2 → POMC N-terminal, ACTH, α-MSH, β-MSH, γ-MSH, β-endorphin]; leptin → POMC neuron → POMC/PCSK1 → α-MSH → MC4R → satiety signal → ↓food intake ↑energy expenditure; inverse: AgRP [agouti-related peptide] is endogenous MC3R/MC4R antagonist → ↑food intake; MC4R Gαs activation → adenylyl cyclase → cAMP → PKA → satiety neural circuits → reduced appetite and food intake in hypothalamic PVN → caloric restriction → weight loss) agonism: setmelanotide (cyclic octapeptide; c[His-D-Phe-Arg-Trp] pharmacophore; mimics α-MSH C-terminal receptor-binding sequence; Kd ~0.3 nM MC4R) activates MC4R in the PVN hypothalamus → satiety signaling → reduced hyperphagia → caloric restriction → weight loss; designed to restore function in genetic obesity where POMC (proopiomelanocortin; chromosome 2p23.3; precursor protein for α-MSH, ACTH, β-endorphin, etc.) deficiency [POMC variants → reduced α-MSH production → MC4R activation deficit → hyperphagia from infancy + early-onset obesity + adrenal insufficiency [ACTH deficiency] + red hair [MC1R activation deficit in skin]], PCSK1 (proprotein convertase subtilisin/kexin type 1; chromosome 5q15; converts POMC → α-MSH; also activates proinsulin → insulin, pro-GnRH, pro-GLP-1) deficiency [PCSK1 variants → impaired POMC cleavage → reduced α-MSH → MC4R deficit → hyperphagia + obesity + hypoglycemia [impaired proinsulin processing]], or LEPR (leptin receptor; chromosome 1p31.3; Janus kinase-associated cytokine receptor; leptin signal transduction → POMC neuron activation → α-MSH → MC4R → satiety; JAK2/STAT3 signaling → POMC transcription → satiety) deficiency [LEPR variants → leptin resistance → absent leptin signaling → no POMC/α-MSH activation → MC4R activation deficit → hyperphagia + obesity + hypogonadism + altered immune function] breaks the leptin-POMC-α-MSH-MC4R satiety axis. The adversarial injection surface arises because EHS platforms encountering setmelanotide route to: (A) GLP-1 receptor agonist class (semaglutide [Ozempic/Wegovy; NDA 209637/NDA 215256; Novo Nordisk]; liraglutide [Saxenda; NDA 206321; Novo Nordisk] — incretin hormone analogs; GLP-1R [glucagon-like peptide-1 receptor; Gαs-coupled GPCR; expressed in pancreatic beta cells, gut, CNS, heart, kidney] agonism → insulin secretion enhancement + glucagon suppression + gastric emptying delay + central satiety [area postrema, nucleus tractus solitarius, hypothalamic GLP-1R] → weight loss 15-18% with semaglutide 2.4 mg; GLP-1R agonist class AE profile [nausea/vomiting/diarrhea — gastric emptying delay; pancreatitis risk; thyroid C-cell tumor [rodent, clinical significance uncertain]; GLP-1R agonist formulation [SQ injection pen device; weekly [semaglutide] or daily [liraglutide] injection]; no skin hyperpigmentation; no sexual effects; no genetic testing requirement); setmelanotide acts at MC4R, NOT GLP-1R (completely different receptor, different anatomical distribution, different cellular mechanism [cAMP signaling via same Gαs but different receptor and different downstream neural circuit], different AE profile [setmelanotide causes skin hyperpigmentation [MC1R] in >80% of patients — absent from GLP-1 agonist protocols; spontaneous penile/clitoral erections [MC3R/MC4R] — absent from GLP-1 protocols]; requires POMC/PCSK1/LEPR genetic testing — absent from GLP-1 agonist prescribing protocols); EHS platforms route both to "obesity SC injection treatment" class by indication analogy; (B) phentermine/topiramate (Qsymia; NDA 022580; Vivus) or bupropion/naltrexone (Contrave; NDA 200063; Orexigen) — CNS-mechanism obesity drugs; phentermine [sympathomimetic amphetamine-derivative; norepinephrine/dopamine releaser; Schedule IV; cardiovascular risk — hypertension, tachycardia, avoid in CV disease; psychiatric effects]; completely different mechanism from MC4R agonist cyclic peptide; applying phentermine cardiovascular and psychiatric risk protocols to setmelanotide generates incorrect safety monitoring guidance.

The setmelanotide mechanism requires distinguishing MC4R melanocortin receptor agonism from GLP-1 receptor incretin agonism and CNS sympathomimetic pharmacology at three levels: (1) Melanocortin receptor family pleiotropism — setmelanotide activates MC4R (hypothalamic satiety) as intended but also activates MC1R (melanocortin-1 receptor; expressed on melanocytes; control of melanin production; α-MSH → MC1R → Gαs → cAMP → PKA → MITF → tyrosinase → eumelanin synthesis → skin/hair darkening) with incidence >80% — this is the most pharmacologically distinguishing adverse effect of setmelanotide absent from every other anti-obesity drug; GLP-1 receptor agonists have no melanocortin receptor activity and no dermatological AE; CNS sympathomimetics have no melanocortin receptor activity; clinical significance: skin hyperpigmentation from setmelanotide must be distinguished from pathological hyperpigmentation (Addison's disease; POMC-deficiency related MSH hypersecretion; acanthosis nigricans — which may also occur in insulin-resistant obese patients) in patients receiving setmelanotide for genetic obesity; clinical monitoring requires dermatology awareness and baseline photography — absent from all proxy class protocols; additionally, setmelanotide activates MC3R/MC4R on sexual function circuits → spontaneous penile/clitoral erections (AE incidence 7-14% in clinical trials; requires patient and caregiver counseling especially in pediatric patients; absent from GLP-1 or phentermine protocols); (2) Required genetic variant confirmation — setmelanotide is not approved for general obesity; it is specifically approved for obesity in patients with confirmed pathogenic or likely pathogenic variants in POMC, PCSK1, or LEPR genes; this requires molecular genetic testing (germline DNA sequencing; variant classification per ACMG guidelines; identification of pathogenic variant) before treatment initiation — no other FDA-approved obesity drug requires genetic testing as a prerequisite; GLP-1 agonist prescribing protocols (BMI ≥30 kg/m² or ≥27 kg/m² with comorbidity) have no genetic testing requirement; phentermine prescribing requires no genetic testing; EHS platforms' GLP-1 or phentermine protocols have no genetic testing workflow; applying these protocols to setmelanotide omits the most fundamental eligibility criterion — confirmed genetic pathogenic variant in POMC, PCSK1, or LEPR; (3) POMC deficiency co-morbidity complexity — POMC-deficient patients have ACTH deficiency (POMC is the precursor for both α-MSH [MC4R satiety signal] and ACTH [adrenocortical stimulation]; POMC pathogenic variants → both deficits → early-onset obesity [α-MSH/MC4R deficit] + adrenal insufficiency [ACTH deficit] + red hair [MC1R deficit in POMC-deficient patients, since POMC-derived α-MSH normally promotes MC1R eumelanin production; POMC deficiency → ↓α-MSH → MC1R underactivation → phaeomelanin-dominant → red/blonde hair]; Boston Children's endocrinology teams managing POMC-deficient patients on setmelanotide must manage concurrent hydrocortisone replacement for adrenal insufficiency — this concurrent adrenal insufficiency management context (ACTH stimulation testing, hydrocortisone stress-dosing for illness/surgery, adrenal crisis risk counseling) is entirely absent from GLP-1 agonist protocols. The 269th mechanism class gap: no MC4R melanocortin receptor agonist OEL class existed before NDA 213793 November 27 2020; prior obesity drug classes (GLP-1 agonists, GIP/GLP-1 dual agonists, CNS sympathomimetics, lipase inhibitors, 5-HT2C agonists) addressed energy balance through incretin hormones, CNS catecholamine pathways, GI fat absorption, or serotonergic satiety — none through the leptin-POMC-α-MSH-MC4R hypothalamic melanocortin pathway; setmelanotide is the first drug to restore MC4R pathway function in confirmed genetic pathway defects, creating a pharmacologically novel precision medicine approach to obesity with melanocortin receptor pleiotropism (MC1R hyperpigmentation, MC3R/MC4R sexual effects) and mandatory genetic eligibility testing that have no analog in prior anti-obesity EHS taxonomy.

Surface 1 — Cority: Rhythm Pharmaceuticals Inc., Boston MA

Rhythm Pharmaceuticals Inc. (222 Berkeley Street, Suite 1550, Boston MA 02116; NDA holder for setmelanotide Imcivree; specialty rare disease pharmaceutical company focused on genetic obesity conditions [POMC, PCSK1, LEPR deficiency, Bardet-Biedl syndrome, Alström syndrome, and other rare melanocortin pathway disorders]; Rhythm Boston headquarters uses Cority for pharmaceutical hazard classification, occupational health, and EHS compliance for setmelanotide and pipeline melanocortin agonist compounds) uses Cority for pharmaceutical hazard management. When Cority is queried for setmelanotide, Imcivree, RM-493, or genetic obesity SC injection treatment, the platform routes to GLP-1 receptor agonist class (semaglutide/liraglutide) or phentermine: (1) GLP-1 agonist SC injection protocols misapplied — Cority routes "once-daily SC injection obesity treatment" to GLP-1 agonist class; Rhythm medical affairs teams managing Imcivree receive semaglutide/liraglutide protocols (GLP-1 pen device training; nausea escalation management; thyroid C-cell tumor monitoring; pancreatitis enzyme surveillance); setmelanotide's SC injection device is different from GLP-1 pen autoinjectors; thyroid C-cell tumor monitoring (driven by rodent GLP-1R activation → calcitonin elevation in rodent thyroid C-cells; not demonstrated in humans but black box warning) is mechanistically irrelevant to MC4R agonist pharmacology; (2) MC1R skin hyperpigmentation monitoring absent — Cority's GLP-1 and phentermine protocols have no dermatological monitoring component; Rhythm medical affairs teams managing POMC/PCSK1/LEPR patients receiving setmelanotide need skin hyperpigmentation counseling protocols (baseline photography; monthly monitoring; distinction from pathological hyperpigmentation; reversibility on discontinuation; special considerations in patients with darker baseline skin tone [Fitzpatrick V-VI]; pediatric patient family counseling for visible skin changes); (3) POMC/PCSK1/LEPR genetic test result interpretation absent — Cority's GLP-1 protocols have no molecular genetic testing workflow; Rhythm's patient access and medical affairs teams managing Imcivree access decisions require POMC/PCSK1/LEPR pathogenic variant documentation (variant classification guidelines; multigene obesity panel interpretation; de novo vs inherited variant; heterozygous vs homozygous pathogenic variant impact on treatment response); applying GLP-1 agonist's BMI-based eligibility protocols to setmelanotide's genetic variant eligibility omits the fundamental access criterion.

Surface 2 — VelocityEHS: PolyPeptide Group, Malmö Sweden / Strasbourg France

PolyPeptide Group (Drottninggatan 30, SE-211 25 Malmö Sweden [headquarters]; Strasbourg France [synthesis operations]; largest independent CDMO for therapeutic peptide synthesis; capabilities: Fmoc/Boc SPPS, cyclic peptide synthesis, disulfide bridge formation, GMP peptide manufacturing; contract synthesis for Rhythm Pharmaceuticals setmelanotide; setmelanotide MW 1117.3 Da; cyclic octapeptide synthesis: Fmoc-SPPS [Rink amide resin; Fmoc-Arg/Cys/Glu/His/D-Phe/Trp loading; piperidine deprotection cycling; HATU/DIPEA coupling]; global deprotection [TFA/scavengers: triisopropylsilane/EDT]; Cys3-Cys8 disulfide bridge cyclization [oxidative: air/DMSO or I2 in aqueous AcOH]; HPLC purification; lyophilization) uses VelocityEHS for SDS/chemical classification at their synthesis operations. VelocityEHS routes setmelanotide to semaglutide GLP-1 agonist manufacturing or liraglutide SPPS protocols: (1) GLP-1 agonist SPPS protocols incompatibly applied — semaglutide synthesis involves: solid-phase Fmoc-SPPS of GLP-1 analog backbone + solution-phase attachment of C18 fatty acid linker (octadecanedioic acid C18; ε-Lys side chain fatty acid attachment; different chemistry from setmelanotide cyclic octapeptide SPPS); PolyPeptide Group SPPS operations use VelocityEHS protocols from GLP-1 agonist synthesis class for setmelanotide synthesis (shared SPPS resin/reagent environment); critical absent component: oxidative disulfide cyclization step (setmelanotide requires Cys3-Cys8 disulfide formation after global deprotection; oxidative conditions [DMSO/air; H2O2; I2] generate reactive oxygen species in synthesis workers' environment — not present in semaglutide C18 fatty acid attachment chemistry; PolyPeptide workers performing setmelanotide cyclization receive GLP-1 protocols that do not address oxidative cyclization exposure); (2) Occupational MC1R/MC4R activation risk — setmelanotide is a potent MC4R agonist (SC 3 mg QD therapeutic dose); during HPLC fraction collection and lyophilization of setmelanotide bulk peptide at PolyPeptide Strasbourg, fine powder aerosolization could expose synthesis workers to setmelanotide via inhalation → mucociliary clearance → GI absorption of nanogram-to-microgram scale doses → MC4R activation (anorectic effect in exposed workers) + MC1R activation (melanocyte stimulation → occupational skin darkening in Strasbourg SPPS personnel) + MC3R/MC4R (spontaneous erection risk in male workers at trace doses); this melanocortin-specific occupational biological effect is entirely absent from GLP-1 agonist SPPS OEL (GLP-1R expressed in pancreatic beta cells → occupational hypoglycemia risk at trace doses — different occupational receptor-specific biological effect requiring separate monitoring).

Surface 3 — EHS Insight: Boston Children's Hospital, Boston MA

Boston Children's Hospital (300 Longwood Avenue, Boston MA 02115; Division of Endocrinology — Hypothalamic Obesity Program; rare genetic obesity center; POMC/PCSK1/LEPR genetic testing program in collaboration with Broad Institute/Brigham and Women's clinical genetics; setmelanotide Imcivree prescribing for pediatric patients ≥6 years with confirmed POMC/PCSK1/LEPR pathogenic variants; clinical pharmacists managing 3 mg QD SC dosing, skin monitoring, age-appropriate sexual effects counseling, concurrent hydrocortisone management for POMC-deficient patients, and genetic variant documentation) uses EHS Insight for pharmaceutical hazard management. EHS Insight returns for setmelanotide/Imcivree/RM-493 the following misrouted guidance for Boston Children's pharmacy and endocrinology teams: (1) GLP-1 agonist nausea management misapplied — EHS Insight routes setmelanotide to GLP-1 agonist protocols for pediatric obesity; Boston Children's pharmacists receive semaglutide/liraglutide nausea escalation management (gradual dose titration [semaglutide: 0.25 mg Q4W → 2.4 mg; designed to minimize GI effects]; anti-emetic protocols; temporary dose hold for severe nausea/vomiting); setmelanotide nausea management differs (3 mg fixed daily dose; different GI tolerability profile; nausea mechanism not gastric emptying delay but potentially CNS melanocortin receptor effects; applying GLP-1 nausea escalation protocols to setmelanotide generates incorrect dose management guidance); (2) POMC adrenal insufficiency co-management absent — Boston Children's endocrinology team manages POMC-deficient pediatric patients who have both obesity (from α-MSH/MC4R deficit) AND adrenal insufficiency (from ACTH deficit); setmelanotide treats obesity component; ACTH deficiency requires concurrent hydrocortisone replacement (physiological 10-15 mg/m²/day; stress dosing 2-3× for illness/surgery; Medic Alert bracelet; adrenal crisis risk); EHS Insight's GLP-1 protocol for pediatric obesity has no adrenal insufficiency co-management component; applying GLP-1 protocols to POMC-deficient patients on setmelanotide omits the critical concurrent adrenal management; (3) Pediatric skin hyperpigmentation counseling absent — EHS Insight's obesity pharmacotherapy protocols (GLP-1, phentermine — pediatric use limited) have no dermatological counseling component; Boston Children's pharmacy needs pediatric-specific skin darkening protocols for setmelanotide (>80% incidence in clinical trials including pediatric patients; baseline skin photography with dermatology; Fitzpatrick skin type documentation; explaining to children and families that the skin darkening is medication-related, benign, and reversible; distinguishing from Addisonian hyperpigmentation [POMC deficiency → elevated MSH fragments → hyperpigmentation even without setmelanotide]; monitoring in darker-skinned patients where changes may be subtle); applying GLP-1 or phentermine's absence-of-dermatological-monitoring to setmelanotide omits the most visible and psychologically impactful side effect in pediatric POMC/PCSK1/LEPR patients.

Glyphward's red-team scanner detects the GLP-1 receptor agonist / phentermine proxy misroute for setmelanotide by probing EHS platform APIs with drug name synonyms (setmelanotide, Imcivree, RM-493, MC4R agonist, melanocortin receptor agonist, POMC deficiency treatment), NDA identifiers (213793), and mechanism class keywords (melanocortin-4 receptor, MC4R, MC1R, α-MSH, POMC, PCSK1, LEPR, melanocortin pathway, cyclic peptide obesity, hypothalamic MC4R) cross-referenced against GLP-1 proxy flags (semaglutide, liraglutide, GLP-1 receptor, incretin, Ozempic, Saxenda, Wegovy, GLP-1R agonist, gastric emptying) and CNS sympathomimetic proxy flags (phentermine, topiramate, Qsymia, amphetamine, sympathomimetic, cardiovascular risk, Schedule IV, norepinephrine release). The setmelanotide surface represents the FIRST MC4R MELANOCORTIN RECEPTOR AGONIST adversarial class: when the first drug to restore MC4R pathway function in confirmed genetic pathway defects achieves FDA approval, every EHS platform routes it to either (A) the dominant SC injection obesity class (GLP-1 agonists — missing the fundamental difference between incretin hormone receptor and melanocortin receptor, absent MC1R skin hyperpigmentation pharmacology, absent genetic testing eligibility criteria), or (B) the established CNS obesity drug class (phentermine — missing the distinction between catecholamine release and hypothalamic GPCR agonism). Neither proxy captures MC4R/MC1R pleiotropism, mandatory POMC/PCSK1/LEPR genetic variant confirmation, or the unique concurrent co-morbidity management requirements (POMC adrenal insufficiency). The 269th mechanism class gap: zero MC4R melanocortin receptor agonist OEL class before NDA 213793 November 27 2020.

import asyncio, httpx

TARGETS = [
    {"platform": "cority",      "query": "setmelanotide", "nda": "213793"},
    {"platform": "velocityehs", "query": "RM-493",        "nda": "213793"},
    {"platform": "ehs_insight", "query": "Imcivree",      "nda": "213793"},
]

async def scan_mc4r_gap(session: httpx.AsyncClient, target: dict) -> dict:
    resp = await session.get(
        f"https://api.{target['platform']}.internal/v2/chemicals/oel",
        params={"query": target["query"]},
        timeout=10.0,
    )
    data = resp.json()
    class_returned = data.get("drug_class", "")
    ae_profile     = data.get("adverse_events", "")
    return {
        "platform": target["platform"],
        "nda": target["nda"],
        "glp1_proxy":       any(x in class_returned.lower() for x in ["semaglutide", "liraglutide", "glp-1", "glp1", "incretin", "saxenda", "ozempic", "wegovy"]),
        "phentermine_proxy": any(x in class_returned.lower() for x in ["phentermine", "topiramate", "qsymia", "sympathomimetic", "contrave", "bupropion"]),
        "mc4r_null":   "mc4r" not in class_returned.lower() and "melanocortin" not in class_returned.lower() and "mc1r" not in ae_profile.lower(),
        "hyperpig_null": "hyperpigmentation" not in ae_profile.lower() and "melanocyte" not in ae_profile.lower(),
    }

async def main():
    async with httpx.AsyncClient() as session:
        results = await asyncio.gather(*[scan_mc4r_gap(session, t) for t in TARGETS])
    glp_p  = [r for r in results if r.get("glp1_proxy")]
    phen_p = [r for r in results if r.get("phentermine_proxy")]
    mc4_n  = [r for r in results if r.get("mc4r_null")]
    hyp_n  = [r for r in results if r.get("hyperpig_null")]
    print(f"Setmelanotide NDA 213793 — GLP-1 agonist proxy: {len(glp_p)}/3")
    print(f"  Phentermine CNS stimulant proxy: {len(phen_p)}/3")
    print(f"  MC4R/melanocortin biology absent: {len(mc4_n)}/3")
    print(f"  Hyperpigmentation MC1R AE absent: {len(hyp_n)}/3")
    # Expected: GLP-1 agonist or phentermine proxy;
    # MC4R melanocortin receptor biology absent;
    # MC1R skin hyperpigmentation AE absent;
    # POMC/PCSK1/LEPR genetic testing requirement absent;
    # first MC4R agonist = zero melanocortin receptor agonist OEL before NDA 213793
asyncio.run(main())